Home › Trials › NCT07405944
Clinical trial Recruiting at 4 sites Phase 4 Interventional Ages 18 and up

Vericiguat for right‑ventricular function and heart remodeling in HFrEF

Official title: Vericiguat's Effects on Reverse Remodeling Indices: Pathophysiologic Approach to Treatment of Heart Failure With Reduced Ejection Fraction

Run by University Medical Centre Ljubljana · NCT07405944 · Data updated 2026-11-12

This study will test whether adding vericiguat to usual heart‑failure treatment helps adults with stable HFrEF improve right‑ventricular function and heart remodeling over 12 months.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment70 (estimated)
SponsorUniversity Medical Centre Ljubljana
Academic / other
Locations4 sites (Izola and 3 other locations)
StatusRecruiting
StartedNovember 1, 2025
Main results expectedJuly 31, 2027
Study endsDecember 31, 2027
Registry record updatedSeptember 29, 2026
Trial IDNCT07405944 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with chronic stable HFrEF (LVEF ≤40%) who have had no heart‑failure worsening requiring hospitalization or outpatient diuretics in the prior 6 months and are on stable guideline‑directed medical therapy for at least 3 months.

Probably not a fit

People with recent decompensation, systolic blood pressure <100 mmHg, current or planned use of long‑acting nitrates or PDE5 inhibitors, certain infiltrative or inflammatory cardiomyopathies, awaiting transplant, or dependent on continuous inotropes are unlikely to be eligible or to receive benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with stable HFrEF on guideline‑directed medical therapy are randomized to vericiguat plus usual care or usual care alone and followed for 12 months. The trial measures right ventricular systolic function by TAPSE and evaluates myocardial structure and biology using cardiac MRI, blood biomarkers, metabolomics, genomics, transcriptomics, OGTTs, and platelet function testing. Outcomes include imaging markers of remodeling, fibrosis, angiogenesis, inflammation, metabolic and renal measures, and hematologic balance, with exploration of genetic and oxidative stress modifiers of response. Approximately 60 participants will be enrolled at a single center in Ljubljana, Slovenia.

Why it matters

Potential benefit: If effective, vericiguat could improve right‑ventricular function and reverse maladaptive remodeling, potentially reducing symptoms and future heart‑failure events.

How similar studies have gone: Large randomized trials such as VICTORIA demonstrated that vericiguat reduces worsening heart‑failure events after recent decompensation, and smaller or emerging analyses suggest possible benefits in stable HFrEF, but its direct effects on remodeling and right‑ventricular function remain incompletely defined.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Written informed consent from an adult patient (≥ 18 years old) to participate in the clinical study,
* Stable HFrEF defined as no heart failure worsening in the 6 months before randomization that required hospitalization or outpatient diuretic treatment,
* Confirmed diagnosis of chronic heart failure with reduced ejection fraction (LVEF \< 50%, confirmed by echocardiography) within 12 months before randomization,
* Stable GDMT for HFrEF for at least 3 months prior to randomisation.

Exclusion Criteria:

* Systolic blood pressure \< 100 mmHg or symptomatic hypotension,
* Current or planned use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type V inhibitors,
* Known allergy/hypersensitivity to soluble guanylate cyclase stimulators,
* Awaiting heart transplantation or dependence on continuous inotropic therapy
* Cardiac amyloidosis, sarcoidosis, myocarditis, stress cardiomyopathy, or tachycardic cardiomyopathy,
* Acute coronary syndrome, coronary artery bypass grafting, or percutaneous coronary intervention in the past three months before randomisation,
* Long-term mechanical circulatory support of the left ventricle,
* Active infection,
* Chronic kidney disease stage 4 or 5, and
* Advanced liver failure classified as Child-Pugh B or C.

Where it's running

  • Division of Internal Medicine, Izola General Hospital
    Izola, Slovenia     Recruiting
  • Clinical Department of Vascular Diseases, University Medical Centre Ljubljana
    Ljubljana, Slovenia     Recruiting
  • University Medical Centre Ljubljana
    Ljubljana, Slovenia     Recruiting
  • University Department of Cardiology and Angiology, University Medical Centre Maribor
    Maribor, Slovenia     Recruiting

Study contacts

  • Principal investigator: Gregor Poglajen, MD, PhD — Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • Study coordinator: Tine Bajec, MD
  • Email: tine.bajec@kclj.si
  • Phone: 051727249

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Heart Failure With Reduced Ejection Fraction (HFrEF) 14Chronic Heart Failure 49University Medical Centre Ljubljana 26
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.